<?xml version="1.0" encoding="UTF-8"?>
<p>In a post hoc analysis of the ICE study, almost half of IVIg responders showed improvement in adjusted INCAT disability scores within the first 3 weeks of treatment (ie, after the initial 2.0 g/kg loading dose).
 <xref rid="jns12267-bib-0018" ref-type="ref">18</xref> To be comparable with data from the ICE study,
 <xref rid="jns12267-bib-0003" ref-type="ref">3</xref> the primary endpoint of the ProCID study will be the proportion of patients in the IVIg 1.0 g/kg group with response to treatment, as defined by an improvement from baseline of â‰¥1 point on the adjusted INCAT disability score. Consistent with the ICE
 <xref rid="jns12267-bib-0003" ref-type="ref">3</xref> and Privigen Impact on Mobility and Autonomy (PRIMA)
 <xref rid="jns12267-bib-0007" ref-type="ref">7</xref> studies, the primary endpoint of this study will be assessed at week 24.
</p>
